A Double-blind Comparison Between Bupropion XL and Venlafaxine XR: Sexual Functioning, Antidepressant Efficacy, and Tolerability

  title={A Double-blind Comparison Between Bupropion XL and Venlafaxine XR: Sexual Functioning, Antidepressant Efficacy, and Tolerability},
  author={Michael E. Thase and Anita H. Clayton and Barbara R. Haight and April H. Thompson and Jack G. Modell and J. Andrew Johnston},
  journal={Journal of Clinical Psychopharmacology},
Abstract: In this double-blind, multicenter study, bupropion XL, a norepinephrine-dopamine reuptake inhibitor, and venlafaxine XR, a serotonin-norepinephrine reuptake inhibitor, were compared with regard to sexual functioning, efficacy, and tolerability. A total of 348 sexually active adult outpatients with depression were randomized to receive bupropion XL (titrated to a target dose of 300-450 mg/d) or venlafaxine XR (titrated to a target dose of 150-225 mg/d) for 12 weeks. Total scores on the… 
A Double-Blind Comparison of Sexual Functioning, Antidepressant Efficacy, and Tolerability Between Agomelatine and Venlafaxine XR
Agomelatine seems to be an efficacious antidepressant with a superior sexual side effect profile compared with venlafaxine XR, although superiority to placebo was not evaluated in this trial.
Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR
Bupropion XR did not demonstrate statistically significant evidence of greater improvement from baseline compared with placebo on week 8 Montgomery Asberg Depression Rating scale scores or on secondary endpoints, and venlafaxine XR indicated separation versus placebo on MADRS total scores at week 8 and other intermediate time points.
Effects of 50 and 100 mg desvenlafaxine versus placebo on sexual function in patients with major depressive disorder: a meta-analysis
The primary objective of this post-hoc analysis was to evaluate the effect of short-term treatment with desvenlafaxine versus placebo on sexual dysfunction (SD), assessed from Arizona Sexual
Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR
In this double-blind, placebo-controlled trial, bupropion XR at doses up to 300 mg/day and venlafaxine XR in adult outpatients with major depressive disorder demonstrated comparable antidepressant efficacy.
Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction.
Switching antidepressant therapy to vortioxetine may be beneficial for patients experiencing sexual dysfunction during antidepressant therapy with SSRIs.
Sexual Side-Effects of Contemporary Antidepressants: Review
The aim of the present study was to review the sexual side-effects of contemporary antidepressants in Australia, comparing the selective serotonin re-uptake inhibitors (SSRIs) with venlafaxine,
Double-blind, placebo-controlled evaluation of extended-release bupropion in elderly patients with major depressive disorder
It is demonstrated that the extended-release bupropion is an effective, well-tolerated treatment for major depression in the elderly.
Efficacy, tolerability, and acceptability of bupropion for major depressive disorder: a meta-analysis of randomized–controlled trials comparison with venlafaxine
Bupropion XL is as effective and tolerable as venlafaxine XR for adult patients with MDD, according to the limited data obtained from three RCTs.
Males and females differ in reported sexual functioning with escitalopram treatment for major depressive disorder: A CAN-BIND-1 study report
For both sexes, sexual satisfaction improves with response to escitalopram, and for females, the response does not correspond to improvements in SF frequency.


Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients.
Both compounds were relatively well tolerated, and orgasm dysfunction, nausea, diarrhea, somnolence, and sweating were reported more frequently in sertraline-treated patients.
Double-blind comparison of bupropion and fluoxetine in depressed outpatients.
Both bupropion and fluoxetine demonstrated similar efficacy in relieving depression and accompanying symptoms of anxiety, and both exhibited a similar, favorable safety profile.
Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine.
An unexpected relationship was found between favorable drug response and a decreased level of drug-induced sexual dysfunction in patients treated with sertraline or paroxetine.
Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction.
The incidence of sexual dysfunction with SSRIs and venlafaxine is high, ranging from 58% to 73%, as compared with serotonin-2 (5-HT2) blockers (nefazodone and mirtazapine), moclobemide, and amineptine.
Bupropion sustained release versus paroxetine for the treatment of depression in the elderly.
Because of its favorable side effect profile, bupropion SR may provide a safe and effective nonserotonergic treatment alternative that is well suited as an antidepressant for the elderly.
Relative antidepressant efficacy of venlafaxine and SSRIs: sex-age interactions.
Findings provide further evidence that age, gender, and HRT moderate response to antidepressant medications.
Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials.
The principal difference between these treatments was that sexual dysfunction commonly complicated SSRI therapy, whereas treatment with bupropion caused no more sexual dysfunction than placebo.
Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
Remission rates were significantly higher with venlafaxine than with an SSRI and the difference between SSRIs and placebo reached significance at week 4, and were not dependent on any one study or the definition of remission.